The use of heparin for treating human malignancies - PubMed

Affiliations

• PMID: 10629404
• DOI: 10.1159/000054112

Review

The use of heparin for treating human malignancies

D L Ornstein et al. Haemostasis. 1999 Dec.

Abstract

There is a substantial amount of data implicating coagulation mechanisms in the pathogenesis of malignancy. Studies in some experimental animal models have shown that the anticoagulant heparin limits tumour growth and metastasis and prolongs survival. Experience with the effects of heparin on human malignancy is limited primarily to settings in which it was given either to prevent or to treat thrombosis in patients who also had cancer. However, these studies have shown noteworthy apparent improvement in cancer outcome with heparin, especially with low-molecular-weight heparin. There are several possible mechanisms by which heparin could potentially alter the natural history of cancer progression because of its ability to modify the cellular and molecular environment of tumour cells. This experience provides the rationale for definitive clinical trials of heparin in patients with cancer and also for further experimentation to define the mechanisms of antineoplastic activity by this familiar class of drugs.

Similar articles

• Heparin as an inhibitor of cancer progression.

  Borsig L. Borsig L. Prog Mol Biol Transl Sci. 2010;93:335-49. doi: 10.1016/S1877-1173(10)93014-7. Prog Mol Biol Transl Sci. 2010. PMID: 20807651 Review.

• Heparin in tumor progression and metastatic dissemination.

  Falanga A, Marchetti M. Falanga A, et al. Semin Thromb Hemost. 2007 Oct;33(7):688-94. doi: 10.1055/s-2007-991536. Semin Thromb Hemost. 2007. PMID: 18000796 Review.

• Antimetastatic activities of heparins and modified heparins. Experimental evidence.

  Borsig L. Borsig L. Thromb Res. 2010 Apr;125 Suppl 2:S66-71. doi: 10.1016/S0049-3848(10)70017-7. Thromb Res. 2010. PMID: 20434009 Review.

• Heparin and cancer.

  Zacharski LR, Ornstein DL. Zacharski LR, et al. Thromb Haemost. 1998 Jul;80(1):10-23. Thromb Haemost. 1998. PMID: 9684778 Review. No abstract available.

• Low-molecular-weight heparin and cancer.

  Zacharski LR, Ornstein DL, Mamourian AC. Zacharski LR, et al. Semin Thromb Hemost. 2000;26 Suppl 1:69-77. doi: 10.1055/s-2000-9499. Semin Thromb Hemost. 2000. PMID: 11011810 Review.

Cited by

• The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways.

  Gockel LM, Ponert JM, Schwarz S, Schlesinger M, Bendas G. Gockel LM, et al. Molecules. 2018 Oct 24;23(11):2753. doi: 10.3390/molecules23112753. Molecules. 2018. PMID: 30356007 Free PMC article.

• Heparin blocks transfer of extracellular vesicles between donor and recipient cells.

  Atai NA, Balaj L, van Veen H, Breakefield XO, Jarzyna PA, Van Noorden CJ, Skog J, Maguire CA. Atai NA, et al. J Neurooncol. 2013 Dec;115(3):343-51. doi: 10.1007/s11060-013-1235-y. Epub 2013 Sep 4. J Neurooncol. 2013. PMID: 24002181 Free PMC article.

• Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis.

  Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Borsig L, et al. Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2193-8. doi: 10.1073/pnas.261704098. Proc Natl Acad Sci U S A. 2002. PMID: 11854515 Free PMC article.

• The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.

  Mueller T, Pfankuchen DB, Wantoch von Rekowski K, Schlesinger M, Reipsch F, Bendas G. Mueller T, et al. Molecules. 2017 May 3;22(5):728. doi: 10.3390/molecules22050728. Molecules. 2017. PMID: 28467373 Free PMC article.

• Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis.

  Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Borsig L, et al. Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3352-7. doi: 10.1073/pnas.061615598. Proc Natl Acad Sci U S A. 2001. PMID: 11248082 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information